Boston Therapeutics
is a pharmaceutical company using complex carbohydrate chemistry to advance its
PAZ320 and IPOXYN drug candidates for the treatment of Type 2 diabetes. With
2013 under wraps, BTHE looks to have an exciting first half of the upcoming
year.
In mid-2014, BTHE
hopes to start a pivotal phase 3 study of PAZ320, a chewable tablet to be taken
before meals to reduce post-meal elevation of blood glucose in Type 2 diabetics
by blocking the action of carbohydrate-hydrolyzing enzymes.
The two-year study,
to be conducted in the U.S., Europe, Hong Kong, Korea, and China, will evaluate
the effects of PAZ320 on glucose and hemoglobin A1c (HbA1c) in approximately
300 Type 2 patients currently taking metformin.
Thus far, Acarbose
is the only drug that has been developed for the non-systemic environment to
prevent glucose formation, though it is accompanied by side effects and limited
functionality. BTHE’s goal is to develop a superior drug without the side effects.
An earlier phase 2
study of PAZ320 suggests that the company is on the right track in doing so. In
the study, 21 patients treated with PAZ320 achieved a 40 percent reduction in
post-meal blood glucose levels with no serious adverse events.
BTHE in November
began enrolling patients in a phase 2b clinical study of PAZ320. A total of 24
patients currently being treated with metformin will receive PAZ320 in a
double-blind, placebo-controlled study. The primary endpoint of the study is to
evaluate the effect of PAZ320 compared to placebo to determine post-meal blood
glucose levels after consumption of a test meal. The company plans to announce
safety and glucose results during the first quarter of 2014.
For more
information, visit www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment